Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
This study is investigating a new way to deliver radiation treatment called Cognitive Sparing Brain Stereotactic Radiosurgery (SRS) for adults with brain metastases (cancer that has spread to the brain). The goal is to protect important brain areas that control memory, thinking, and attention during radiation. Researchers will use advanced imaging to identify these critical brain regions. They want to see if this approach improves verbal memory, executive functioning (planning and problem-solving skills), and attention/processing speed three months after treatment, compared to standard radiation. You may be able to join if you are 18 or older, have one to three brain metastases smaller than 3 cm, and have a good performance status (meaning you're mostly able to get around and do daily activities). The study is currently unclear on its recruitment status and plans to enroll 60 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 60 participants, but the phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for changes in cognitive function up to 3 months after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jona Hattangadi-Gluth, MD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in Verbal Memory from baseline to 3 months after SRSChange from Baseline (pre-treatment) to 3 months post treatment
To evaluate the change from baseline to 3-month post-SRS verbal memory performance when performing relative sparing of eloquent white matter tracts and hippocampi from high doses during brain SRS in patients with 1 to 3 brain metastases. Verbal memory outcomes and measurements include: Hopkins Verbal Learning Test-Revised (HVLT-R)-Immediate, Delayed Recall. Scale of scores is 0-36 for Immediate, 0-12 for Delayed. For both tests, higher scores indicate better performance.
- Change in Executive Functioning from baseline to 3 months after SRSChange from Baseline (pre-treatment) to 3 months post treatment
To evaluate the change from baseline to 3-month post-SRS executive functioning performance when performing relative sparing of eloquent white matter tracts and hippocampi from high doses during brain SRS in patients with 1 to 3 brain metastases. Executive functioning outcomes and measurements include: Controlled Oral Word Association Test (COWA): letter fluency, Trail Making Test Part B (TMT-B). Scale of scores is: Controlled Oral Word Association Test (COWA): letter fluency: 0- no upper limit. Higher score indicates better performance Trail Making Test Part B (TMT-B): 0-240. Higher score indicates poorer performance
- Change in Attention/Processing Speed from baseline to 3 months after SRSChange from Baseline (pre-treatment) to 3 months post treatment
To evaluate the change from baseline to 3-month post-SRS Attention/Processing Speed performance when performing relative sparing of eloquent white matter tracts and hippocampi from high doses during brain SRS in patients with 1 to 3 brain metastases. Attention/Processing Speed outcomes and measurements include: Trail Making Test Part A (TMT-A) Scale of scores is: Trail Making Test Part A (TMT-A): 0-240. Higher score indicates poorer performance
- Change in Language functioning from baseline to 3 months after SRSChange from Baseline (pre-treatment) to 3 months post treatment
To evaluate the change from baseline to 3-month post-SRS Language performance when performing relative sparing of eloquent white matter tracts and hippocampi from high doses during brain SRS in patients with 1 to 3 brain metastases. Language outcomes and measurements include: Boston Naming Test (BNT), Controlled Oral Word Association Test (COWA): category fluency Scale of scores is: Boston Naming Test (BNT): 0-60 Controlled Oral Word Association Test (COWA): category fluency: 0-no upper limit For both tests, higher score indicates better performance.